Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takuya Osada

Showing results (131-140 of 132) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 132 results.
Annals of Surgery|May 10, 2013
A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancerMichael A Morse, Donna Niedzwiecki, John L Marshall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
Intratumoral Plasmid IL12 Expands CD8<sup>+</sup> T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 TherapyMelinda L Telli, Hiroshi Nagata, Irene Wapnir, et al.
Pageof 14

Showing results (131-140 of 132) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 132 results.
Annals of Surgery|May 10, 2013
A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancerMichael A Morse, Donna Niedzwiecki, John L Marshall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
Intratumoral Plasmid IL12 Expands CD8<sup>+</sup> T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 TherapyMelinda L Telli, Hiroshi Nagata, Irene Wapnir, et al.
Pageof 14